Why Co-Diagnostics Skyrocketed 28.3% Today

After the Food and Drug Administration approved collaboration partner Clinical Reference Laboratory's saliva test for COVID-19, Co-Diagnostics (NASDAQ: CODX) shares soared 28.3% on Monday.

One of the biggest private lab companies in the United States, Clinical Reference Laboratory (CRL) developed its saliva COVID-19 test using Co-Diagnostics CoPrimer technology to boost sensitivity and reduce false positives by eliminating amplification errors common in molecular testing.

IMAGE SOURCE: GETTY IMAGES.

Continue reading

Source Fool.com